Melanoma vaccine - POP Biotechnologies
Latest Information Update: 21 Jan 2026
At a glance
- Originator POP Biotechnologies
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Malignant melanoma
Most Recent Events
- 05 Nov 2025 Early research in Malignant melanoma in USA (Parenteral) (POP Biotechnologies pipeline, November 2025)